Priority Review Voucher Extension Scaled Back In New Cures Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Pediatric rare disease program would have been renewed for seven years under previous draft, but now would only have a three-year on life as full committee mark-up begins.